Online inquiry

IVTScrip™ mRNA-Anti-SLITRK6, AGS15C(Cap 0, Pseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ1940MR)

This product GTTS-WQ1940MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 0 & Pseudo-UTP. It ecodes the monoclonal antibody that targets SLITRK6 gene. The antibody can be applied in Cancers research.
Specifications
Product type mRNA
Modified bases Pseudo-UTP
5' Cap Cap 0
Species Homo sapiens
RefSeq NM_032229.3
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 84189
UniProt ID Q9H5Y7
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-SLITRK6, AGS15C(Cap 0, Pseudo-UTP, 30 nt-poly(A)) (GTTS-WQ1940MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ3760MR IVTScrip™ mRNA-Anti-CEACAM6, BAY-1834942(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA BAY-1834942
GTTS-WQ8273MR IVTScrip™ mRNA-Anti-GHR, HM10560A(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA HM10560A
GTTS-WQ3699MR IVTScrip™ mRNA-Anti-MSLN, BAY 2287409(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA BAY 2287409
GTTS-WQ8751MR IVTScrip™ mRNA-Anti-TNFRSF4, IBI-101(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA IBI-101
GTTS-WQ3794MR IVTScrip™ mRNA-Anti-Factor VIIa substitute, BAY-86-6150(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA BAY-86-6150
GTTS-WQ4147MR IVTScrip™ mRNA-Anti-PDCD1, BI-754091(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA BI-754091
GTTS-WQ12441MR IVTScrip™ mRNA-Anti-IFNG, NI-0501(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA NI-0501
GTTS-WQ2111MR IVTScrip™ mRNA-Anti-IFNAR1&IFNAR2, Alb-IFNA2 R23 (608)(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA Alb-IFNA2 R23 (608)
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW